Table 1 Descriptive statistics of study cohorts
Demographics | Overall N = 277 | NLR < 5 N = 239 | NLR ≥ 5 N = 38 | P Value | PLR < 144.4 N = 139 | PLR ≥ 144.4 N = 138 | P Value | LMR ≤ 2.9 N = 140 | LMR > 2.9 N = 137 | P Value |
|---|---|---|---|---|---|---|---|---|---|---|
Age, median (range), y | 68.0 (33.0–90.0) | 68.0 (33.0–90.0) | 67.5 (47.0–86.0) | .396 | 69.0 (40.0–90.0) | 66.5 (33.0–86.0) | .384 | 68.0 (33.0–86) | 67.0 (40.0–90.0) | .083 |
Sex, no. (%) | Â | Â | Â | .715 | Â | Â | .103 | Â | Â | .239 |
 Female | 120 (43.3) | 102 (42.7) | 18 (47.4) |  | 53 (38.1) | 67 (48.6) |  | 66 (47.1) | 54 (39.4) |  |
 Male | 157 (56.7) | 137 (57.3) | 20 (52.6) |  | 86 (61.9) | 71 (51.4) |  | 74 (52.9) | 83 (60.6) |  |
Race, no. (%) | Â | Â | Â | .166 | Â | Â | .279 | Â | Â | .383 |
 Black | 11 (3.97) | 11 (4.60) | 0 (0.00) |  | 3 (2.16) | 8 (5.80) |  | 4 (2.86) | 7 (5.11) |  |
 Other | 11 (3.97) | 8 (3.35%) | 3 (7.89) |  | 5 (3.60) | 6 (4.35) |  | 4 (2.86) | 7 (5.11) |  |
 White | 255 (92.1) | 220 (92.1%) | 35 (92.1) |  | 131 (94.2) | 124 (89.9) |  | 132 (94.3) | 123 (89.8) |  |
BMI, median (range) | 26.3 (16.7–58.5) | 26.4 (16.7–58.5) | 26.2 (18.6–44.1) | .841 | 26.3 (16.7–46.7) | 26.3 (16.7–58.5) | .976 | 26.4 (16.7–55.7) | 26.2 (16.7–58.5) | .848 |
CCI, no. (%) | Â | Â | Â | .646 | Â | Â | .900 | Â | Â | .157 |
 0–3 | 69 (24.9) | 58 (24.3) | 11 (28.9) |  | 33 (23.7) | 36 (26.1) |  | 28 (20.0) | 41 (29.9) |  |
 4–5 | 136 (49.1) | 120 (50.2) | 16 (42.1) |  | 69 (49.6) | 67 (48.6) |  | 74 (52.9) | 62 (45.3) |  |
  ≥ 6 | 72 (26.0) | 61 (25.5) | 11 (28.9) |  | 37 (26.6) | 35 (25.4) |  | 38 (27.1) | 34 (24.8) |  |
Tumor Size | 2.70 (0.08–8.20) | 2.70 (0.08–8.20) | 2.70 (0.60–6.50) | .593 | 3.00 (0.10–8.20) | 2.5 (0.08–7.00) | .028 | 2.60 (0.08–7.00) | 2.90 (0.10–8.20) | .123 |
Pathologic Stage, no. (%) | Â | Â | Â | .439 | Â | Â | .126 | Â | Â | .642 |
 T0 | 18 (6.55) | 17 (7.17) | 1 (2.63%) |  | 9 (6.52) | 9 (6.57) |  | 11 (7.91) | 7 (5.15) |  |
 T1, no. (%) | 23 (8.36) | 18 (7.59) | 5 (13.2) |  | 16 (11.6) | 7 (5.11) |  | 10 (7.19) | 13 (9.56) |  |
 T2, no. (%) | 132 (48.0) | 116 (48.9) | 16 (42.1) |  | 69 (50.0) | 63 (46.0) |  | 69 (49.6) | 63 (46.3) |  |
 T3 | 102 (37.1) | 86 (36.3) | 16 (42.1) |  | 44 (31.9) | 58 (42.3) |  | 49 (35.3) | 53 (39.0) |  |
Preoperative Resectability, no. (%) | Â | Â | Â | .186 | Â | Â | .005 | Â | Â | <.001 |
 Borderline | 101 (36.5) | 83 (34.7) | 18 (47.4) |  | 39 (28.1) | 62 (44.9) |  | 68 (48.6) | 33 (24.1) |  |
 Resectable | 176 (63.5) | 156 (65.3) | 20 (52.6) |  | 100 (71.9) | 76 (55.1) |  | 72 (51.4) | 104 (75.9) |  |
Neoadjuvant Therapy, no. (%) | Â | Â | Â | .204 | Â | Â | .008 | Â | Â | <.001 |
 No | 175 (63.2) | 155 (64.9) | 20 (52.6) |  | 99 (71.2) | 76 (55.1) |  | 71 (50.7) | 104 (75.9) |  |
 Yes | 102 (36.8) | 84 (35.1) | 18 (47.4) |  | 40 (28.8) | 62 (44.9) |  | 69 (49.3) | 33 (24.1) |  |
Margin, no. (%) | Â | Â | Â | 1.00 | Â | Â | 1.00 | Â | Â | .145 |
 Negative | 249 (89.9) | 215 (90.0) | 34 (89.5) |  | 125 (89.9) | 124 (89.9) |  | 130 (92.9) | 119 (86.9) |  |
 Positive | 28 (10.1) | 24 (10.0) | 4 (10.5) |  | 14 (10.1) | 14 (10.1) |  | 10 (7.14) | 18 (13.1) |  |
Lymphovascular Invasion, no. (%) | Â | Â | Â | 1.00 | Â | Â | .855 | Â | Â | .188 |
 No | 83 (30.5) | 72 (30.5) | 11 (30.6) |  | 43 (31.4) | 40 (29.6) |  | 47 (34.6) | 36 (26.5) |  |
 Yes | 189 (69.5) | 164 (69.5) | 25 (69.4) |  | 94 (68.6) | 95 (70.4) |  | 89 (65.4) | 100 (73.5) |  |
Perineural Invasion, no. (%) | Â | Â | Â | .606 | Â | Â | .680 | Â | Â | .159 |
 No | 50 (18.4) | 45 (19.1) | 5 (13.9) |  | 27 (19.7) | 23 (17.0) |  | 30 (22.1) | 20 (14.7) |  |
 Yes | 222 (81.6) | 191 (80.9) | 31 (86.1) |  | 110 (80.3) | 112 (83.0) |  | 106 (77.9) | 116 (85.3) |  |
Complication 3-4a, no. (%) | Â | Â | Â | .604 | Â | Â | .359 | Â | Â | 1.00 |
 No | 241 (87.0) | 209 (87.4) | 32 (84.2) |  | 124 (89.2) | 117 (84.8) |  | 122 (87.1) | 119 (86.9) |  |
 Yes | 36 (13.0) | 30 (12.6) | 6 (15.8) |  | 14 (10.8) | 21 (15.2) |  | 18 (12.9) | 18 (13.1) |  |
Completion of Adjuvant Therapy, no. (%) | Â | Â | Â | .155 | Â | Â | 1.00 | Â | Â | .166 |
 No | 97 (35.8) | 79 (33.9) | 18 (47.4) |  | 48 (35.6) | 49 (36.0) |  | 55 (40.1) | 42 (31.3) |  |
 Yes | 174 (64.2) | 154 (66.1) | 20 (52.6) |  | 87 (64.4) | 87 (64.0) |  | 82 (59.9) | 92 (68.7) |  |